Your trusted destination for CME, CPD & Medical Education across the Middle East.
King Faisal Specialist Hospital, Saudi Arabia
Dr. Zeyad Al Shaibani is an eminent consultant hematologist, stem cell transplantation expert, and clinical researcher based at King Faisal Specialist Hospital & Research Centre (KFSH&RC) in Riyadh, Saudi Arabia. He earned his Doctor of Medicine (MD) degree with distinguished academic honors, followed by structured postgraduate residency training in internal medicine. Driven to attain master-level expertise in complex hematologic diseases, he completed subspecialty fellowship training in adult hematology in Canada, earning Fellowship status with the Royal College of Physicians and Surgeons of Canada (FRCPC), followed by advanced clinical fellowships in adult hematopoietic stem cell transplantation (HSCT) and immune cellular therapies at leading international academic centers.
Practicing within the Department of Hematology & Bone Marrow Transplantation at KFSH&RC—one of the Middle East’s primary tertiary and quaternary referral centers for complex blood disorders—Dr. Al Shaibani leads specialized clinical pathways for patients with high-acuity non-malignant and malignant hematologic conditions. His clinical scope encompasses severe aplastic anemia, acquired bone marrow failure syndromes, paroxysmal nocturnal hemoglobinuria (PNH), autoimmune hemolytic anemia, refractory immune thrombocytopenia (ITP), hemoglobinopathies, and allogeneic and autologous stem cell transplantation.
Throughout his clinical tenure, Dr. Al Shaibani has been a key figure in introducing advanced immunosuppressive protocols and targeted complement-inhibitor therapies into routine clinical workflows across the GCC. He works closely with transfusion medicine specialists, hematopathologists, molecular geneticists, and intensive care teams to establish standardized diagnostic workups for rare classical hematology syndromes, significantly reducing diagnostic delays and improving long-term patient survival outcomes.
Recognizing the evolving paradigm in classical hematology, Dr. Al Shaibani has spearheaded the clinical implementation of novel complement-targeted pharmacotherapies (such as C5 and Factor B/D inhibitors) and advanced T-cell depletion strategies for haploidentical stem cell transplants. His efforts have enabled patients with severe aplastic anemia and refractory autoimmune cytopenias to achieve sustained hematologic remissions while minimizing treatment-related toxicity and graft-versus-host disease (GVHD).
In addition to his bedside clinical responsibilities and transplant unit leadership, Dr. Al Shaibani is a dedicated academic faculty member and clinical educator. He actively supervises adult hematology fellows, internal medicine residents, and clinical research scholars, directing CME-accredited bone marrow morphology seminars, translational immunology workshops, and transplant conditioning protocols. His instructional philosophy emphasizes translating complex pathophysiology into precise, evidence-based diagnostic algorithms and individualized therapeutic plans.
Dr. Al Shaibani is a prolific physician-scientist who has authored numerous peer-reviewed scientific publications in leading high-impact hematology journals, including Blood, Transplantation and Cellular Therapy, British Journal of Haematology, and Bone Marrow Transplantation. His active research portfolio focuses on evaluating long-term outcomes of allogeneic stem cell transplantation in non-malignant blood disorders, characterizing genomic biomarkers in acquired aplastic anemia, and assessing real-world safety and efficacy metrics of targeted therapies for complement-mediated hematologic diseases in Middle Eastern patient cohorts.
Beyond his institutional leadership at KFSH&RC, Dr. Al Shaibani serves on several regional and international scientific steering committees, clinical trial advisory boards, and rare disease consortia. He actively collaborates with international hematology societies to formulate evidence-based consensus guidelines, establish Middle Eastern rare anemia registries,and advance patient access to cutting-edge clinical trials across the MENA region.
At the International Classical Hematology Conference 2026 (ICCH 2026), Dr. Zeyad Al Shaibani stands out as a core scientific leader and keynote speaker. Bridging molecular mechanisms with bedside clinical practice, he provides hematologists, internists, transfusion medicine specialists, and clinical researchers with practical strategies to optimize classical hematology protocols, master targeted therapeutics, and elevate care standards for patients worldwide.

MeetingMinds Experts
MeetingMinds Experts